Clinical trial: Oral drug keeps cancer treatment on track for patients who develop persistently low platelet counts. In a phase 2 clinical trial, Mass General Brigham Cancer Institute researchers found that the oral drug avatrombopag was safe and effective in managing persistent chemotherapy-induced thrombocytopenia (CIT) in more than half of patients with gastrointestinal cancers, offering a potential new option for managing a common and challenging complication of cancer treatment.
A apuração publicada por medicalxpress.com vira base para uma leitura editorial direta e contextualizada.
Trechos de apoio da pauta: In a phase 2 clinical trial, Mass General Brigham Cancer Institute researchers found that the oral drug avatrombopag was safe and effective in managing persistent chemotherapy-induced thrombocytopenia (CIT) in more than half of patients with gastrointestinal cancers, offering a potential new option for managing a common and challenging complication of cancer treatment. Their work is published in the Journal of Clinical Oncology.
- Ponto de atenção: clinical.
- Ponto de atenção: trial.
- Ponto de atenção: oral.
Em resumo, a leitura editorial acompanha o impacto do tema no nicho Saúde.
